Alistair Wheeler, MD MFPM - Chief Medical Officer

Alistair joined Spyryx in 2016 to lead the Company's clinical development operations, medical affairs and regulatory strategy.   He brings to the Company nearly 35 years of global drug development experience, including work across all phases of development with both small molecules and biologics.  He has been personally responsible for over 30 INDs/CTAs and had key roles in the filing of nine successful marketing applications with regulatory agencies worldwide.  A large majority of this work has been focused in the respiratory field, developing products for nasal allergy, rhinitis, asthma, COPD, and pneumonia.  Additionally, Alistair’s family has a connection to Cystic Fibrosis that fuels his passion to make a meaningful impact for these patients as well.

Prior to joining Spyryx, Alistair was the Global Head of Clinical Development, Respiratory Medicine and Biotherapeutics at Sunovion Pharmaceuticals, where he was responsible for all clinical development activities, including the recent NDA filing for SUN-101 in COPD which he led from Phase 2 onward, and the support of clinical expansion for Sunovion's approved products in multiple therapeutic areas.  Before Sunovion, Alistair was Senior Director, Clinical Research at Cubist Pharmaceuticals, leading the clinical research function for development programs in infectious disease and cardiovascular surgery, as well as leading the clinical support for marketed products.  Alistair’s earlier clinical development and medical affairs experience included positions in both the US and Europe at Avant Immunotherapeutics, Astra USA, Hoffmann-LaRoche, and Glaxo. 

Alistair earned his MD from the Royal London Hospital Medical College and his MFPM from the Royal College of Physicians.  He is a member of the American Thoracic Society and former vice president of the American Academy of Pharmaceutical Physicians.